US · DCTH
Delcath Systems, Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- New York City, NY 10019
- Website
- delcath.com
Price · as of 2025-12-31
$10.80
Market cap 308.83M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $116.22 | +976.11% |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $0.00 | $0.00 | |||
| 2018 | $180.60 | $606.06 | $0.00 | $0.00 | $0.00 |
| 2019 | $11.00 | $1,019.62 | $0.00 | $0.00 | $14,788.89 |
| 2020 | $18.90 | $25.61 | $0.00 | $0.00 | $0.00 |
| 2021 | $6.22 | $28.45 | $0.02 | $0.00 | $0.00 |
| 2022 | $4.71 | $15.10 | $0.00 | $0.00 | $59.48 |
| 2023 | $3.98 | $17.99 | $0.00 | $0.00 | $43.55 |
| 2024 | $13.00 | $254.78 | $1,433.41 | $0.00 | $0.00 |
| 2025 | $8.93 | $116.22 |
AI valuation
Our deep-learning model estimates Delcath Systems, Inc.'s (DCTH) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $116.22
- Current price
- $10.80
- AI upside
- +976.11%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| DCTH | Delcath Systems, Inc. | $10.80 | 308.83M | +976% | — | — | — | 118.48 | 2.88 | — | 59.54 | — | 2.88 | 0.00% | — | — | 3.00% | 2.70% | 2.70% | 0.01 | — | 10.92 | 9.39 | -11.02 | -10756.00% | -10000.00% | -20899.00% | 6.56% | 2.06 | 111.33% | 0.00% | 0.00% | 3.63% | 348.16 | 10.96 | — | 10.54 |
| AGL | Agilon Health, Inc. | $0.59 | 244.31M | +3,319% | +1,042% | — | — | -0.65 | 2.01 | 0.04 | 0.03 | -1.17 | 4.18 | -3.18% | -7.10% | -6.83% | -130.95% | 2821.09% | -26.04% | 0.15 | -63.41 | 1.02 | 0.89 | 0.42 | 5556.00% | -211.00% | 6755.00% | -46.67% | -0.10 | 797.30% | 0.00% | 0.00% | 2.97% | 0.03 | 0.09 | 0.00 | 1.55 |
| BWAY | BrainsWay Ltd. | $23.14 | 453.81M | +186% | +74% | -80% | -73% | 54.72 | 2.56 | 3.90 | 17.94 | — | 2.56 | 74.56% | 3.39% | 7.12% | 5.62% | -43.99% | 3.71% | 0.09 | 1.03 | 5.19 | 4.82 | -11.89 | -16923.00% | 2904.00% | -68966.00% | 4.07% | 0.67 | -243.55% | 0.00% | 0.00% | 33.58% | 69.09 | 14.78 | 2.34 | 2.84 |
| CERS | Cerus Corporation | $2.56 | 491.74M | +1,048% | -13% | — | — | -13.30 | 4.96 | 1.55 | -29.56 | — | 5.08 | 55.21% | -7.89% | -11.60% | -38.53% | -18.17% | -10.52% | 1.75 | -1.60 | 2.39 | 1.73 | -7.76 | -4762.00% | 1529.00% | -11784.00% | 3.06% | 0.18 | 10.88% | 0.00% | 0.00% | 2.34% | -20.83 | 34.77 | 1.64 | -5.07 |
| MASS | 908 Devices Inc. | $6.90 | 249.73M | +193% | -84% | — | — | -1.30 | 0.82 | 1.58 | -0.71 | -1.49 | 1.36 | 50.18% | -128.65% | -121.09% | -51.56% | -197.59% | -39.84% | 0.06 | — | 4.10 | 3.27 | 0.85 | 8761.00% | 1872.00% | 1382.00% | -32.80% | -1.20 | -79.76% | 0.00% | 0.00% | 0.00% | -0.40 | -1.01 | 0.52 | -1.50 |
| NAKA | Nakamoto Inc. | $0.25 | 92.19M | +34,449% | +169% | — | +4,954% | -2.46 | 3.46 | 3.27 | -2.47 | -1.66 | 4.08 | 96.96% | -123.05% | -133.01% | -294.13% | -619.29% | -151.45% | 0.31 | -8.51 | 4.13 | 3.81 | 0.50 | 14815.00% | -2783.00% | 64918.00% | -39.07% | -5.07 | -643.12% | 0.00% | 0.00% | 18.24% | -2.21 | -2.13 | 2.72 | 0.21 |
| NPCE | NeuroPace, Inc. | $14.58 | 485.63M | +102% | +40% | — | — | -11.80 | 39.98 | 4.01 | -20.57 | — | 39.98 | 73.94% | -27.12% | -33.97% | -189.35% | -78.53% | -26.83% | 9.15 | -2.46 | 5.37 | 4.33 | -3.61 | -2677.00% | 2214.00% | -815.00% | -5.70% | -1.18 | -66.15% | 0.00% | 0.00% | 0.00% | -15.73 | -18.68 | 4.27 | -4.71 |
| RXST | RxSight, Inc. | $7.48 | 307.55M | +291% | -36% | -74% | — | — | 1.14 | 2.33 | -2.43 | — | 1.14 | 76.60% | -35.84% | -28.96% | 0.00% | -83.88% | 0.00% | 0.04 | -1204.75 | 10.95 | 9.58 | 0.22 | 3380.00% | -389.00% | -1360.00% | -6.17% | -0.59 | -33.66% | 0.00% | — | 1.44% | -2.00 | -4.98 | 0.72 | 3.16 |
| SENS | Senseonics Holdings, Inc. | $8.27 | 337.9M | +200% | +728% | — | — | -5.18 | -24.61 | 18.13 | -5.73 | -38.01 | -23.91 | 2.37% | -333.05% | -349.84% | -817.17% | 267.39% | -65.88% | -3.69 | -8.87 | 2.35 | 2.13 | 0.20 | 1364.00% | 37.00% | -1107.00% | -15.39% | -1.56 | 224.02% | 0.00% | 0.00% | 0.00% | -5.26 | -6.28 | 17.53 | -12.73 |
| SMLR | Semler Scientific, Inc. | $20.33 | 310.75M | +321% | +54% | +196% | — | 6.57 | 1.17 | 4.78 | 11.81 | 6.92 | 16.68 | 91.55% | 37.19% | 72.65% | 27.04% | 15.50% | 25.73% | 0.00 | — | 3.59 | 3.06 | -0.41 | 9506.00% | -1744.00% | 1881.00% | 9.06% | 3.87 | 21.12% | 0.00% | 0.00% | 0.00% | 12.13 | 10.43 | 4.51 | 18.96 |
| TCMD | Tactile Systems Technolog… | $29.29 | 657.24M | +114% | +65% | -58% | -43% | — | 3.06 | 2.03 | 16.77 | — | 4.51 | 75.17% | 8.89% | 5.79% | 0.00% | 11.72% | 0.00% | 0.07 | 28.21 | 4.03 | 3.11 | -1.88 | 1714.00% | 1247.00% | 599.00% | 6.03% | 1.05 | 26.58% | 0.00% | — | 6.69% | 20.58 | 14.90 | 1.83 | 9.68 |
About Delcath Systems, Inc.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
- CEO
- Gerard J. Michel
- Employees
- 96
- Beta
- 0.37
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $10.80) − 1 = — (DCF, example).